Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model

Ho Kyoung Hwang, Takashi Murakami, Tasuku Kiyuna, SeHoon Kim, Sung Hwan Lee, ChangMoo Kang, Robert M. Hoffman, Michael Bouvet

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The purpose of this study was to investigate whether splenectomy influences the tumor growth and metastatic pattern in an orthotopic syngeneic murine pancreatic cancer model. Murine pancreatic cancer cells (PAN02) were subcutaneously injected into the flanks of nude mice. A small tumor fragment (3 mm2), harvested from a subcutaneous tumor. was orthotopically implanted in the tail of the pancreas of C57/BL6 mice without splenectomy (control group, n=15) or with simultaneous splenectomy (splenectomy group, n=15). Tumor growth and metastatic patterns were analyzed by laparotomy at 21 days after surgery. No tumor growth was found in 5 mice (33.3%) of the control group and 1 mouse (6.7%) of the splenectomy group (p=0.169). Tumor volume was significantly larger in splenectomy group (p=0.013). Peritoneal seeding was more frequently observed in the splenectomy group (11 (73.3%) vs. 4 (26.7%), p=0.011). There were no differences in the number of liver and kidney metastasis between the two groups. The ratios of tumor-infiltrating CD4+ to FoxP3+ and CD8+ to FoxP3+ were significantly higher in the control group compared to the splenectomy group (8.2 ± 9.3 vs. 2.4 ± 1.5, p=0.046; 2.5 ± 1.4 vs. 1.5 ± 0.4, p=0.031, respectively). Splenectomy enhanced tumor growth and peritoneal seeding in an orthotopic syngeneic murine pancreatic cancer mouse model. The ramification of these results are discussed for pancreatic cancer treatment.

Original languageEnglish
Pages (from-to)88827-88834
Number of pages8
JournalOncotarget
Volume8
Issue number51
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Splenectomy
Pancreatic Neoplasms
Immunity
Growth
Neoplasms
Control Groups
Tumor Burden
Ambulatory Surgical Procedures
Nude Mice
Laparotomy
Tail
Pancreas
Neoplasm Metastasis
Kidney
Liver

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Hwang, Ho Kyoung ; Murakami, Takashi ; Kiyuna, Tasuku ; Kim, SeHoon ; Lee, Sung Hwan ; Kang, ChangMoo ; Hoffman, Robert M. ; Bouvet, Michael. / Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model. In: Oncotarget. 2017 ; Vol. 8, No. 51. pp. 88827-88834.
@article{ff2ab472792b45809bde7624857b70dd,
title = "Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model",
abstract = "The purpose of this study was to investigate whether splenectomy influences the tumor growth and metastatic pattern in an orthotopic syngeneic murine pancreatic cancer model. Murine pancreatic cancer cells (PAN02) were subcutaneously injected into the flanks of nude mice. A small tumor fragment (3 mm2), harvested from a subcutaneous tumor. was orthotopically implanted in the tail of the pancreas of C57/BL6 mice without splenectomy (control group, n=15) or with simultaneous splenectomy (splenectomy group, n=15). Tumor growth and metastatic patterns were analyzed by laparotomy at 21 days after surgery. No tumor growth was found in 5 mice (33.3{\%}) of the control group and 1 mouse (6.7{\%}) of the splenectomy group (p=0.169). Tumor volume was significantly larger in splenectomy group (p=0.013). Peritoneal seeding was more frequently observed in the splenectomy group (11 (73.3{\%}) vs. 4 (26.7{\%}), p=0.011). There were no differences in the number of liver and kidney metastasis between the two groups. The ratios of tumor-infiltrating CD4+ to FoxP3+ and CD8+ to FoxP3+ were significantly higher in the control group compared to the splenectomy group (8.2 ± 9.3 vs. 2.4 ± 1.5, p=0.046; 2.5 ± 1.4 vs. 1.5 ± 0.4, p=0.031, respectively). Splenectomy enhanced tumor growth and peritoneal seeding in an orthotopic syngeneic murine pancreatic cancer mouse model. The ramification of these results are discussed for pancreatic cancer treatment.",
author = "Hwang, {Ho Kyoung} and Takashi Murakami and Tasuku Kiyuna and SeHoon Kim and Lee, {Sung Hwan} and ChangMoo Kang and Hoffman, {Robert M.} and Michael Bouvet",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.21331",
language = "English",
volume = "8",
pages = "88827--88834",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "51",

}

Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model. / Hwang, Ho Kyoung; Murakami, Takashi; Kiyuna, Tasuku; Kim, SeHoon; Lee, Sung Hwan; Kang, ChangMoo; Hoffman, Robert M.; Bouvet, Michael.

In: Oncotarget, Vol. 8, No. 51, 01.01.2017, p. 88827-88834.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model

AU - Hwang, Ho Kyoung

AU - Murakami, Takashi

AU - Kiyuna, Tasuku

AU - Kim, SeHoon

AU - Lee, Sung Hwan

AU - Kang, ChangMoo

AU - Hoffman, Robert M.

AU - Bouvet, Michael

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The purpose of this study was to investigate whether splenectomy influences the tumor growth and metastatic pattern in an orthotopic syngeneic murine pancreatic cancer model. Murine pancreatic cancer cells (PAN02) were subcutaneously injected into the flanks of nude mice. A small tumor fragment (3 mm2), harvested from a subcutaneous tumor. was orthotopically implanted in the tail of the pancreas of C57/BL6 mice without splenectomy (control group, n=15) or with simultaneous splenectomy (splenectomy group, n=15). Tumor growth and metastatic patterns were analyzed by laparotomy at 21 days after surgery. No tumor growth was found in 5 mice (33.3%) of the control group and 1 mouse (6.7%) of the splenectomy group (p=0.169). Tumor volume was significantly larger in splenectomy group (p=0.013). Peritoneal seeding was more frequently observed in the splenectomy group (11 (73.3%) vs. 4 (26.7%), p=0.011). There were no differences in the number of liver and kidney metastasis between the two groups. The ratios of tumor-infiltrating CD4+ to FoxP3+ and CD8+ to FoxP3+ were significantly higher in the control group compared to the splenectomy group (8.2 ± 9.3 vs. 2.4 ± 1.5, p=0.046; 2.5 ± 1.4 vs. 1.5 ± 0.4, p=0.031, respectively). Splenectomy enhanced tumor growth and peritoneal seeding in an orthotopic syngeneic murine pancreatic cancer mouse model. The ramification of these results are discussed for pancreatic cancer treatment.

AB - The purpose of this study was to investigate whether splenectomy influences the tumor growth and metastatic pattern in an orthotopic syngeneic murine pancreatic cancer model. Murine pancreatic cancer cells (PAN02) were subcutaneously injected into the flanks of nude mice. A small tumor fragment (3 mm2), harvested from a subcutaneous tumor. was orthotopically implanted in the tail of the pancreas of C57/BL6 mice without splenectomy (control group, n=15) or with simultaneous splenectomy (splenectomy group, n=15). Tumor growth and metastatic patterns were analyzed by laparotomy at 21 days after surgery. No tumor growth was found in 5 mice (33.3%) of the control group and 1 mouse (6.7%) of the splenectomy group (p=0.169). Tumor volume was significantly larger in splenectomy group (p=0.013). Peritoneal seeding was more frequently observed in the splenectomy group (11 (73.3%) vs. 4 (26.7%), p=0.011). There were no differences in the number of liver and kidney metastasis between the two groups. The ratios of tumor-infiltrating CD4+ to FoxP3+ and CD8+ to FoxP3+ were significantly higher in the control group compared to the splenectomy group (8.2 ± 9.3 vs. 2.4 ± 1.5, p=0.046; 2.5 ± 1.4 vs. 1.5 ± 0.4, p=0.031, respectively). Splenectomy enhanced tumor growth and peritoneal seeding in an orthotopic syngeneic murine pancreatic cancer mouse model. The ramification of these results are discussed for pancreatic cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=85031917541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031917541&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21331

DO - 10.18632/oncotarget.21331

M3 - Article

VL - 8

SP - 88827

EP - 88834

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 51

ER -